Caprock Mining Corp
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 102
- Market Cap
- $155.6M
- Website
- http://www.capricor.com
- Introduction
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
Phase 1
Terminated
- Conditions
- Myocardial Infarction
- Interventions
- Drug: PlaceboBiological: CAP-1002 Allogeneic Cardiosphere-Derived Cells
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Capricor Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT01458405
- Locations
- 🇺🇸
SUMMA Health System, Akron, Ohio, United States
🇺🇸University of Florida - Shands Hospital, Gainesville, Florida, United States
🇺🇸Austin Heart, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath